Edoxaban and the need for outcomes-based NOAC dosing.
Publication
, Journal Article
Patel, MR; Washam, JB
Published in: Lancet
June 6, 2015
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
Lancet
DOI
EISSN
1474-547X
Publication Date
June 6, 2015
Volume
385
Issue
9984
Start / End Page
2232 / 2233
Location
England
Related Subject Headings
- Thiazoles
- Pyridines
- Humans
- General & Internal Medicine
- Factor Xa Inhibitors
- Atrial Fibrillation
- 42 Health sciences
- 32 Biomedical and clinical sciences
- 11 Medical and Health Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Patel, M. R., & Washam, J. B. (2015). Edoxaban and the need for outcomes-based NOAC dosing. Lancet, 385(9984), 2232–2233. https://doi.org/10.1016/S0140-6736(14)62289-3
Patel, Manesh R., and Jeffrey B. Washam. “Edoxaban and the need for outcomes-based NOAC dosing.” Lancet 385, no. 9984 (June 6, 2015): 2232–33. https://doi.org/10.1016/S0140-6736(14)62289-3.
Patel MR, Washam JB. Edoxaban and the need for outcomes-based NOAC dosing. Lancet. 2015 Jun 6;385(9984):2232–3.
Patel, Manesh R., and Jeffrey B. Washam. “Edoxaban and the need for outcomes-based NOAC dosing.” Lancet, vol. 385, no. 9984, June 2015, pp. 2232–33. Pubmed, doi:10.1016/S0140-6736(14)62289-3.
Patel MR, Washam JB. Edoxaban and the need for outcomes-based NOAC dosing. Lancet. 2015 Jun 6;385(9984):2232–2233.
Published In
Lancet
DOI
EISSN
1474-547X
Publication Date
June 6, 2015
Volume
385
Issue
9984
Start / End Page
2232 / 2233
Location
England
Related Subject Headings
- Thiazoles
- Pyridines
- Humans
- General & Internal Medicine
- Factor Xa Inhibitors
- Atrial Fibrillation
- 42 Health sciences
- 32 Biomedical and clinical sciences
- 11 Medical and Health Sciences